로딩 중…
StockDiggingStockDigging

YUHAN CORPORATION

000100· KOSPI
₩76,100-2.69%
2026-06-19

Price Chart

YUHAN CORPORATION-24.73%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap6.06T KRW
Revenue2.22T KRW
Net Income208.62B KRW
Total Assets3.28T KRW
Net Assets2.34T KRW
Employees2,117
Value
P/E29.05x
P/B2.59x
PEG0.18x
P/S2.73x
EV/EBITDA211.66x
FCF Yield0.11%
Profitability
ROE8.91%
ROA6.37%
Op. Margin4.81%
Revenue Growth7.16%
Earnings Growth164.72%
Financial Health
Debt Ratio40.03%
Total Debt354.82B KRW
FCF6.63B KRW
Cash388.91B KRW
Current Ratio2.03x
Net Debt/EBITDA-1.20x
Dividend
Div. Yield0.77%
Div. Growth20.00%
Performance
1Y Return-24.73%
1M Return-6.63%
From 52W High-44.21%
1Y MDD-46.69%
Trading
Volume393,824 shares
Foreign Own.18.64%
Per Share
EPS2,617 KRW
BPS30,611 KRW

Company Info

CEO 대표이사 조욱제
Employees 2,117
Founded 1926
HQ 서울특별시 동작구, KR

Established in 1926 and listed on the securities market in 1962, the company is a leading pharmaceutical firm, with 14 companies under its umbrella, including a subsidiary slated for KOSDAQ listing in 2025. Its primary business is the manufacturing and sale of pharmaceuticals and chemical products, including key products like Leclaza. The company is building an innovative network by adopting AI and big data for new drug development, collaborating with global pharmaceutical companies, and conducting joint R&D with bio-ventures and universities. The company is headquartered in Dongjak-gu, Seoul.